Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorine F 18-BMS-986229 is a radiopharmaceutical diagnostic agent consisting of a macrocyclic peptide (BMS-986229) labeled with the positron-emitting isotope fluorine‑18. It is designed as a high-affinity, selective ligand for programmed death-ligand 1 (PD-L1), enabling noninvasive imaging of PD-L1 expression in tumors using positron emission tomography (PET). The tracer demonstrates rapid clearance from non–PD-L1-expressing tissues and strong, specific binding to PD-L1, allowing for assessment of spatial heterogeneity in PD-L1 expression. It was developed using BMS‑986189 as the starting scaffold and optimized for radiolabeling and imaging performance. The primary clinical application is in oncology diagnostics, particularly to guide immunotherapy decisions by visualizing PD-L1 status in cancers such as gastroesophageal adenocarcinoma[1][2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluorine F 18-BMS-986229.